Publikationen in Zusammenarbeit mit Forschern von Universitat Pompeu Fabra (21)

2024

  1. Substance use disorders and cooperative research on addictions: Spanish approach as a model

    Pharmacological Research, Vol. 206

2022

  1. Acute stress and alcohol exposure during adolescence result in an anxious phenotype in adulthood: Role of altered glutamate/endocannabinoid transmission mechanisms

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 113

2019

  1. Inflammatory mediators and dual depression: Potential biomarkers in plasma of primary and substance-induced major depression in cocaine and alcohol use disorders

    PLoS ONE, Vol. 14, Núm. 3

2018

  1. Impaired Spermatogenesis, Muscle, and Erythrocyte Function in U12 Intron Splicing-Defective Zrsr1 Mutant Mice

    Cell Reports, Vol. 23, Núm. 1, pp. 143-155

  2. Octadecylpropyl sulfamide reduces neurodegeneration and restores the memory deficits induced by hypoxia-ischemia in mice

    Frontiers in Pharmacology, Vol. 9, Núm. APR

2016

  1. Nalmefene is effective at reducing alcohol seeking, treating alcohol-cocaine interactions and reducing alcohol-induced histone deacetylases gene expression in blood

    British Journal of Pharmacology, pp. 2490-2505

2015

  1. Histone Deacetylase Gene Expression Following Binge Alcohol Consumption in Rats and Humans

    Alcoholism: Clinical and Experimental Research, Vol. 39, Núm. 10, pp. 1939-1950

  2. Pharmacological blockade of the fatty acid amide hydrolase (FAAH) alters neural proliferation, apoptosis and gliosis in the rat hippocampus, hypothalamus and striatum in a negative energy context

    Frontiers in Cellular Neuroscience, Vol. 9

  3. Plasma Concentrations of BDNF and IGF-1 in abstinent cocaine users with high prevalence of substance use disorders: Relationship to psychiatric comorbidity

    PLoS ONE, Vol. 10, Núm. 3

  4. Plasma profile of pro-inflammatory cytokines and chemokines in cocaine users under outpatient treatment: Influence of cocaine symptom severity and psychiatric co-morbidity

    Addiction Biology, Vol. 20, Núm. 4, pp. 756-772

  5. Sex differences in psychiatric comorbidity and plasma biomarkers for cocaine addiction in abstinent cocaine-addicted subjects in outpatient settings

    Frontiers in Psychiatry, Vol. 6, Núm. FEB

  6. Treatment with a novel oleic-acid-dihydroxyamphetamine conjugation ameliorates non-alcoholic fatty liver disease in obese Zucker rats

    DMM Disease Models and Mechanisms, Vol. 8, Núm. 10, pp. 1213-1225

2014

  1. The systemic administration of oleoylethanolamide exerts neuroprotection of the nigrostriatal system in experimental Parkinsonism

    International Journal of Neuropsychopharmacology, Vol. 17, Núm. 3, pp. 455-468

2013

  1. Diet-dependent modulation of hippocampal expression of endocannabinoid signaling-related proteins in cannabinoid antagonist-treated obese rats

    European Journal of Neuroscience, Vol. 37, Núm. 1, pp. 105-117

  2. Evaluation of plasma-free endocannabinoids and their congeners in abstinent cocaine addicts seeking outpatient treatment: Impact of psychiatric co-morbidity

    Addiction Biology, Vol. 18, Núm. 6, pp. 955-969

2012

  1. Unsaturated fatty alcohol derivatives of olive oil phenolic compounds with potential low-density lipoprotein (LDL) antioxidant and antiobesity properties

    Journal of Agricultural and Food Chemistry, Vol. 60, Núm. 4, pp. 1067-1074

2010

  1. Effects of the endogenous PPAR-α agonist, oleoylethanolamide on MDMA-induced cognitive deficits in mice

    Synapse, Vol. 64, Núm. 5, pp. 379-389

  2. Synthesis of fatty acid amides of catechol metabolites that exhibit antiobesity properties

    ChemMedChem, Vol. 5, Núm. 10, pp. 1781-1787

2009

  1. Oleoylethanolamide exerts partial and dose-dependent neuroprotection of substantia nigra dopamine neurons

    Neuropharmacology, Vol. 56, Núm. 3, pp. 653-664

2002

  1. Cannabinoid Addiction: Behavioral Models and Neural Correlates

    Journal of Neuroscience